Company Description
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe.
The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma.
The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe.
The company was founded in 1988 and is headquartered in Queensbury, New York.
| Country | United States |
| Founded | 1988 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 156 |
| CEO | Gerard Michel |
Contact Details
Address: 566 Queensbury Avenue Queensbury, New York 12804 United States | |
| Phone | 212 489 2100 |
| Website | delcath.com |
Stock Details
| Ticker Symbol | DCTH |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000872912 |
| CUSIP Number | 24661P807 |
| ISIN Number | US24661P8077 |
| Employer ID | 06-1245881 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Gerard J. Michel MBA, MS | Chief Executive Officer and Director |
| Dr. Martha S. Rook Ph.D. | Chief Operating Officer |
| Dr. Vojislav Vukovic M.D., M.Sc., Ph.D. | Chief Medical Officer |
| Sandra Pennell CPA | Chief Financial Officer |
| David Hoffman J.D. | General Counsel, Corporate Secretary and Chief Compliance Officer |
| Dr. Johnny John M.D. | Senior Vice President of Clinical Operations and Medical Affairs |
| Dr. Michael Brunner M.D. | Senior Vice President of Interventional Oncology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 3, 2026 | 8-K | Current Report |
| Feb 26, 2026 | 10-K | Annual Report |
| Feb 26, 2026 | 8-K | Current Report |
| Feb 10, 2026 | SCHEDULE 13D/A | Filing |
| Jan 12, 2026 | 8-K | Current Report |
| Nov 20, 2025 | 8-K | Current Report |
| Nov 4, 2025 | 10-Q | Quarterly Report |
| Nov 4, 2025 | 8-K | Current Report |
| Oct 20, 2025 | 8-K | Current Report |
| Oct 17, 2025 | SCHEDULE 13G | Filing |